ATI2341 does not protect from vascular leakiness. (a and b) Vascular leakiness in SCD administered with vehicle or ATI2341 without (left) and with TNF-α administration (right); n = 4 mice per group. (c) Vascular leakiness in vehicle- and ATI2341-treated mice in basal conditions (left) and after LPS challenge (right); n = 4 mice per group. (d) Vascular leakiness in vehicle- and ATI2341-treated mice in basal conditions and after induction of AMI; n = 3–4 mice per group. Data in a and b are from a single experiment. Data in c and d are pooled from two experiments. Data are shown as the mean ± SEM. ns, not significant, as determined by two-way ANOVA a, c, and d and unpaired t test (b).